MiR-93-5p is a Novel Predictor of Coronary In-stent Restenosis

Overview

Journal Heart Asia

Date 2019 Apr 30

PMID 31031831

Citations 10

Authors

John F OSullivan

Antoinette Neylon

Eoin F Fahy

Pengyi Yang

Catherine McGorrian

Gavin J Blake

Affiliations

Soon will be listed here.

Abstract

Aims: MicroRNAs (miRNAs), small non-coding RNAs, have been implicated as regulators of multiple phases of atherothrombosis, and some reports have suggested altered levels in coronary artery in-stent restenosis (ISR). We recently demonstrated that miR-93-5 p was able to discriminate between patients with stable coronary artery disease (CAD) and those with no CAD, after adjusting for traditional risk factors (RFs). Thus, we wanted to determine if circulating miRNAs could predict coronary ISR.

Objective: To determine if circulating miRNAs have diagnostic capability for determining ISR in a cohort of matched patients with and without ISR.

Approach And Results: To determine if miRNA plasma levels are elevated in coronary ISR, we conducted a study comprising 78 patients (39 with no ISR and 39 with ISR) and measured plasma miRNAs in each. We then determined the predictive ability of differential miRNAs, adjusting for Framingham Heart Study (FHS) RFs, and stent length and diameter, to discriminate between ISR and no ISR. After correction for multiple testing, two miRNAs-miR425-5p and miR-93-5 p-were differential between patients with ISR and patients without ISR. Only miR-93-5 p remained a strong independent predictor of ISR after correction for FHS RFs (OR 6.30, p=0.008) and FHS RFs plus stent length and diameter (OR 4.80, p=0.02) and improved discriminatory power for ISR over FHS RFs alone in receiver operator characteristic curve analysis.

Conclusion: This novel finding that miR-93-5 p independently predicts ISR extends our recent observation that miR-93-5 p predicted CAD after adjustment for traditional CAD RFs. These data suggest further potential diagnostic utility.

Citing Articles

Increased intracellular miR-142 in adults with Type 1 diabetes.

Huang L, Januszewski A, Takahashi Y, ONeal D, Ma J, Jenkins A J Diabetes Complications. 2023; 37(10):108597.

PMID: 37659140 PMC: 10592019. DOI: 10.1016/j.jdiacomp.2023.108597.

MiRNA-93: a novel signature in human disorders and drug resistance.

Hussen B, Abdullah S, Rasul M, Jawhar Z, Faraj G, Kiani A Cell Commun Signal. 2023; 21(1):79.

PMID: 37076893 PMC: 10114484. DOI: 10.1186/s12964-023-01106-3.

Noncoding RNAs in Vascular Cell Biology and Restenosis.

Efovi D, Xiao Q Biology (Basel). 2023; 12(1).

PMID: 36671717 PMC: 9855655. DOI: 10.3390/biology12010024.

Roles of MicroRNAs in Peripheral Artery In-Stent Restenosis after Endovascular Treatment.

Wang M, Zhang W, Zhang L, Wang L, Li J, Shu C Biomed Res Int. 2021; 2021:9935671.

PMID: 34368362 PMC: 8337102. DOI: 10.1155/2021/9935671.

Targeting the epigenome in in-stent restenosis: from mechanisms to therapy.

Yang X, Yang Y, Guo J, Meng Y, Li M, Yang P Mol Ther Nucleic Acids. 2021; 23:1136-1160.

PMID: 33664994 PMC: 7896131. DOI: 10.1016/j.omtn.2021.01.024.

References

Stettler C, Wandel S, Allemann S, Kastrati A, Morice M, Schomig A . Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007; 370(9591):937-48. DOI: 10.1016/S0140-6736(07)61444-5. View

DAgostino Sr R, Vasan R, Pencina M, Wolf P, Cobain M, Massaro J . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6):743-53. DOI: 10.1161/CIRCULATIONAHA.107.699579. View

Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico M . The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 2009; 16(12):1590-8. PMC: 3014107. DOI: 10.1038/cdd.2009.153. View

Faul F, Erdfelder E, Buchner A, Lang A . Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41(4):1149-60. DOI: 10.3758/BRM.41.4.1149. View

Wang G, Zhu J, Zhang J, Li Q, Li Y, He J . Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010; 31(6):659-66. DOI: 10.1093/eurheartj/ehq013. View

DAlessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla P . Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010; 31(22):2765-73. PMC: 2980809. DOI: 10.1093/eurheartj/ehq167. View

Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C . Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010; 107(5):677-84. DOI: 10.1161/CIRCRESAHA.109.215566. View

Stolker J, Kennedy K, Lindsey J, Marso S, Pencina M, Cutlip D . Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry. Circ Cardiovasc Interv. 2010; 3(4):327-34. DOI: 10.1161/CIRCINTERVENTIONS.110.946939. View

Qin S, Zhang C . MicroRNAs in vascular disease. J Cardiovasc Pharmacol. 2010; 57(1):8-12. PMC: 4517184. DOI: 10.1097/FJC.0b013e318203759b. View

10.

OSullivan J, Martin K, Caplice N . Microribonucleic acids for prevention of plaque rupture and in-stent restenosis: "a finger in the dam". J Am Coll Cardiol. 2011; 57(4):383-9. DOI: 10.1016/j.jacc.2010.09.029. View

11.

Lovren F, Pan Y, Quan A, Singh K, Shukla P, Gupta N . MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation. 2012; 126(11 Suppl 1):S81-90. DOI: 10.1161/CIRCULATIONAHA.111.084186. View

12.

Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S . Functional screening identifies miRNAs inducing cardiac regeneration. Nature. 2012; 492(7429):376-81. DOI: 10.1038/nature11739. View

13.

Hazarika S, Farber C, Dokun A, Pitsillides A, Wang T, Lye R . MicroRNA-93 controls perfusion recovery after hindlimb ischemia by modulating expression of multiple genes in the cell cycle pathway. Circulation. 2013; 127(17):1818-28. PMC: 3856290. DOI: 10.1161/CIRCULATIONAHA.112.000860. View

14.

Ren J, Zhang J, Xu N, Han G, Geng Q, Song J . Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. PLoS One. 2013; 8(12):e80738. PMC: 3855151. DOI: 10.1371/journal.pone.0080738. View

15.

OSullivan J, Neylon A, McGorrian C, J Blake G . MicroRNA Expression in Coronary Artery Disease. Microrna. 2014; 2(3):205-11. DOI: 10.2174/22115366113026660018. View

16.

He M, Gong Y, Shi J, Pan Z, Zou H, Sun D . Plasma microRNAs as potential noninvasive biomarkers for in-stent restenosis. PLoS One. 2014; 9(11):e112043. PMC: 4245195. DOI: 10.1371/journal.pone.0112043. View

17.

Loo J, Scherl A, Nguyen A, Man F, Weinberg E, Zeng Z . Extracellular metabolic energetics can promote cancer progression. Cell. 2015; 160(3):393-406. PMC: 4312495. DOI: 10.1016/j.cell.2014.12.018. View

18.

He Y, Lin L, Cao J, Mao X, Qu Y, Xi B . Up-regulated miR-93 contributes to coronary atherosclerosis pathogenesis through targeting ABCA1. Int J Clin Exp Med. 2015; 8(1):674-81. PMC: 4358498. View

19.

Acharya S, Fendler W, Watson J, Hamilton A, Pan Y, Gaudiano E . Serum microRNAs are early indicators of survival after radiation-induced hematopoietic injury. Sci Transl Med. 2015; 7(287):287ra69. PMC: 4686271. DOI: 10.1126/scitranslmed.aaa6593. View

20.

McDonald R, Halliday C, Miller A, Diver L, Dakin R, Montgomery J . Reducing In-Stent Restenosis: Therapeutic Manipulation of miRNA in Vascular Remodeling and Inflammation. J Am Coll Cardiol. 2015; 65(21):2314-27. PMC: 4444526. DOI: 10.1016/j.jacc.2015.03.549. View